氯吡格雷联合阿司匹林与单用阿司匹林治疗急性轻型卒中或短暂性脑缺血发作的疗效比较
基于韩国全国多中心前瞻性卒中登记数据库,纳入符合CHANCE试验标准的急性轻型缺血性卒中或短暂性脑缺血发作患者5590例,采用倾向评分逆概率加权调整基线差异。结果显示,与单用阿司匹林相比,氯吡格雷联合阿司匹林与3个月内卒中、心肌梗死及血管性死亡的复合终点风险降低相关(HR 0.76,95%CI 0.63-0.92)。
要点
- 在符合CHANCE标准的急性轻型非心源性缺血性卒中患者中,氯吡格雷联合阿司匹林与3个月血管事件风险降低相关。
- 联合治疗与全因卒中事件风险降低相关(HR 0.74,95%CI 0.61-0.90)。
- 既往使用抗血小板药物、年龄≥75岁及非小血管病机制的患者可能获益更明显。
核心结论
- 在急性轻型非心源性缺血性卒中的3个月内,阿司匹林联合氯吡格雷双联抗血小板治疗与卒中、心肌梗死和血管性死亡风险降低相关。
- 获益可能在既往使用抗血小板药物、年龄较大及非小血管病卒中机制的患者中更为明显。
研究设计与样本
- 研究为基于韩国全国多中心前瞻性卒中登记数据库的观察性比较研究。
- 纳入符合CHANCE试验资格标准的患者5590例,年龄64±13岁,男性占62.6%。
- 采用倾向评分逆概率加权调整基线不平衡,主要终点为3个月内全部卒中、心肌梗死及血管性死亡的复合终点。
主要发现
- 未调整分析中,氯吡格雷联合阿司匹林组与阿司匹林组3个月主要血管事件发生率分别为9.9%与12.2%(HR 0.79,95%CI 0.67-0.95)。
- 倾向加权Cox回归中,联合治疗与主要血管事件风险降低相关(HR 0.76,95%CI 0.63-0.92)。
- 联合治疗与全部卒中事件风险降低相关(HR 0.74,95%CI 0.61-0.90)。
- 6项预设亚组分析中3项显示潜在效应修饰:无既往抗血小板使用(P交互=0.01)、年龄<75岁(P交互=0.07)获益较小,小血管闭塞亚型(P交互=0.08)未见获益。
关键数值与推荐
- 急性轻型缺血性卒中定义为NIHSS评分≤3或病灶阳性的短暂性脑缺血发作,且发病24小时内。
- 卒中机制为非心源性。
- 阿司匹林组占66.1%,氯吡格雷联合阿司匹林组占33.9%。
临床怎么用
- 对于符合CHANCE样标准的急性轻型非心源性缺血性卒中或短暂性脑缺血发作患者,可考虑阿司匹林联合氯吡格雷双联抗血小板治疗以降低3个月血管事件风险。
- 既往使用抗血小板药物、年龄较大及非小血管病机制的患者可能从双联治疗中获益更多,小血管闭塞亚型未见获益需个体化评估。
局限性
- 研究为观察性登记分析,尽管采用倾向评分逆概率加权,仍可能存在未测量混杂。
- 亚组交互作用P值仅部分达到统计学显著(P交互=0.01),部分为边缘性(P交互=0.07、0.08),亚组结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- This study aimed to compare the effectiveness of dual antiplatelet therapy with clopidogrel-aspirin to that of aspirin monotherapy in patients with acute minor cerebral ischemia using a prospective, nationwide, multicenter, stroke registry database in South Korea. Methods- CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events)-like patients who met eligibility criteria modeled on the CHANCE trial eligibility criteria, including (1) acute minor ischemic stroke defined as National Institutes of Health Stroke Scale score ≤3 or lesion positive transient ischemic attack within 24 hours of onset and (2) noncardioembolic stroke mechanism. Propensity scores using the inverse probability of treatment weighting was used to adjust for baseline imbalances. The primary outcome was the composite of all stroke (ischemic and hemorrhagic), myocardial infarction, and vascular death by 3 months. Results- Among 5590 patients meeting the eligibility criteria, age was 64±13 year and 62.6% were male. Aspirin and combination of clopidogrel-aspirin were administered in 66.1% and 33.9% of patients, respectively. In unadjusted analysis, rates of the 3-month primary vascular event outcome were lower with clopidogrel-aspirin versus aspirin, 9.9% versus 12.2% (hazard ratio, 0.79 [0.67-0.95]). In propensity-weighted Cox proportional hazards regression with robust estimation, clopidogrel-aspirin was associated with a lower risk of the primary vascular event outcome (hazard ratio, 0.76 [0.63-0.92]) and all stroke events (hazard ratio, 0.74 [0.61-0.90]). Among 6 predefined subgroup analyses, 3 showed potential modification of treatment effect, with lesser benefit associated with the absence of prior antiplatelet use (Pinteraction=0.01) and younger age (<75 years, Pinteraction=0.07), and absence of benefit associated with small vessel occlusion subtype (Pinteraction=0.08). Conclusions- Dual antiplatelet therapy with aspirin and clopidogrel was associated with reduced stroke, myocardial infarction, and vascular death in the 3 months following a presenting minor, noncardioembolic ischemic stroke. Benefits may be particularly magnified in patients with a history of prior antiplatelet therapy, older age, and nonsmall vessel disease stroke mechanism.
引用
- Kim JT, Park MS, Choi KH, et al. Comparative Effectiveness of Aspirin and Clopidogrel Versus Aspirin in Acute Minor Stroke or Transient Ischemic Attack. Stroke. 2018. PMID: 30580722. doi:10.1161/STROKEAHA.118.022691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。